BRF awards grant to Kinaxo to expand phosphoproteomics platform

Germany's Kinaxo Biotechnologies GmbH has been awarded a grant by the Bavarian Research Foundation to expand applications for its  quantitative phosphoproteomics platform to contribute to a drug  efficacy study.

Quantitative phoshpoproteomics enables analysis of the phosphoproteome,  which includes all phosphorylation events occurring in a specific cell  line or tissue. Since the majority of targeted small molecules used as  anticancer drugs influence the cell's signal transduction pathways,  quantification of phosphorylation patterns in relation to drug  administration delivers insights into a compound's cellular mode of  action, Kinaxo noted.

To develop new methods for individualized tumor therapy in pancreatic  cancer, Kinaxo has now joined an interdisciplinary collaboration with  Priaxon AG, Genomatix Software GmbH, the Technical University Munich and  the University Hospital Rechts der Isar to perform a large-scale drug  efficiency study.